Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder (Q34575850)

3 August 2017

1 reference

title

Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder (English)

1 reference

3 August 2017

Norman Zinner

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

511-523

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Estimated economic costs of overactive bladder in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Defining overactive bladder: epidemiology and burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

M(3) muscarinic receptors mediate contraction of human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea pig urinary bladder and submandibular salivary gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Pharmacological Effects of Darifenacin on Human Isolated Urinary Bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

The clinical pharmacokinetics of darifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

An investigation of dose titration with darifenacin, an M3-selective receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Assessment of cognitive function of the elderly population: effects of darifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

The responsiveness of the Overactive Bladder Questionnaire (OAB-q).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.4.511

21 January 2018

Identifiers

DOI

10.1517/14656566.8.4.511

1 reference

3 August 2017

1 reference